HOME >> BIOLOGY >> NEWS
AutovaxID-C introduced by Biovest International

Biovest International, Inc. (Symbol: BVTI.OB), a biopharmaceutical company focused on the development of patient specific immunotherapeutics and automated cell culture instrumentation, presented its newest cell culture instrument, the AutovaxIDTM-C, at the Cancer Research Institute's recent meeting titled "Cancer Vaccines: Barriers, Endpoints and Opportunities." This was the first introduction of the AutovaxIDTM-C to the biotech industry.

The AutovaxID-C is an automated hollow fiber cell culture instrument that collects secreted protein from cells and controls the growth of the cells automatically for 30 days or more. Growth takes place in sterile, disposable patient specific modules that are bar coded for ease of tracking and identification. Biovest believes that the AutovaxID-C instrument represents a significant advance in personalized medicine because it reduces the possibility of cross contamination and allows segregation of patient specific vaccine batches. Further expected advantages include reduced manpower requirements, automated batch record generation and improved efficiency in facility design.

"Cancer vaccines are one of the most exciting and promising fields of personalized medicine," said Carl M. Cohen, Ph.D., Chief Operating Officer, Biovest. "The production of a patient specific vaccine to immunize individuals against their own cancers has been a goal of investigators in both academia and industry. Biovest is currently testing an idiotype vaccine to treat follicular non-Hodgkin's lymphomas in a Phase 3 clinical trial."

"Our approach is unique in that it uses hybridoma technology to produce complete idiotype proteins identical to those on the tumor B cells. Results from early clinical trials are very encouraging and generating a lot of excitement in the medical community; however, there has been some concern about the challenge of producing personalized vaccines on a large scale. At this meeting
'"/>

Contact: James McNulty
jamcnulty@biovest.com
813-864-2554
SciWords
8-Dec-2005


Page: 1 2

Related biology news :

1. AutovaxID-C introduced by Accentia Biopharmaceuticals
2. First SCID gene chip to be introduced at Academy meeting on immunodeficiencies
3. Ape computers introduced in the US
4. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
5. Biovest International submits amendment request to FDA for use of molecular remission data
6. Biovest International announces that it will report new follow-up data
7. National Ecological Observatory Network featured at ESA/SER Joint International Conference
8. International team to honor 30th anniversary of deep-sea vent discovery in Galpagos
9. 2nd International EuroFIR Congress
10. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
11. Smithsonian hosts Polar Science Symposium to celebrate International Polar Year 2007-2008

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/7/2020)... ... August 06, 2020 , ... Alucio™, a fast-growing provider ... Eric Chen and Jessica Wong have joined the company’s leadership team as Vice ... Eric Chen heads development efforts for Alucio’s flagship product, Beacon, an innovative cloud-based ...
(Date:8/5/2020)... Fla. (PRWEB) , ... August 05, 2020 , ... Regenative ... cover two new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts ... defect using a syringe. The company’s solutions are the first Wharton’s jelly allograft product ...
(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. today announced a ... Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the Department of ... a highly efficient mammalian cell culture-based bioprocess suitable to meet surge requirement needs ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 12, 2020 , ... ... International), a global leader in FDA compliance consulting has been named on its ... companies. The list represents a unique look at the most successful companies within ...
(Date:7/31/2020)... ... ... R3 Stem Cell International is now offering patients the opportunity to receive four ... may choose which extremities they would like treated. , Several studies have shown just ... R3 International, umbilical cord tissue is obtained from a lab with a long history ...
(Date:7/31/2020)... ... July 29, 2020 , ... Editas ... global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, ... entered into a strategic partnership whereby Catalent will provide support for the development, ...
(Date:7/22/2020)... ... July 22, 2020 , ... Join experts from Reed Tech ... Regulatory Solutions, in a one hour live webinar on Thursday, August 13, ... China for drugs and medical devices. Specifically, for medical devices, the NMPA has departments ...
Breaking Biology Technology:
Cached News: